摘要
利用慢病毒(LV)“体外”局部基因治疗载体过表达骨形成蛋白-2(BMP-2)是提高动物模型的骨愈合的一种有效方法。在这里,我们评估了两种不同的“体外”实验方法,使用的是“同一天”的大鼠骨髓细胞(SDRBMCs)或体外培养的大鼠骨髓细胞(C-RBMCs),基于两步激活系统过表达GFP(LV-TSTA-EGFP),两者均通过慢病毒转导,观察转染细胞的生存和这种方法的安全性。转导的细胞植入同系大鼠股骨缺损处。术后4、14、28及56天处死动物(n = 5只/每组)。病毒的复制在SD-RBMC组缺损部位进行检测和逐渐下降8w(相比4d减少了5 log)。在SD-RBMC动物中,有在2w、4w的病毒拷贝数下降2-4 log,但在8w有相对增加(约100倍)在4缺损部位的病毒载体的数量(5)动物相比之前的时间点。对于这两种基因转移的方法,组织分布的模式是非特异性的,并且在任何一组中都没有组织学异常。总之,我们证明了LV-TSTA转导的细胞至少在缺损部位保持56天,虽然数量随时间的延长而下降。在内部器官的病毒复制中没有一致的结果,用于人类的这种策略的相关发展是令人鼓舞的。
关键词: 病毒载体分布,骨修复,体外基因治疗及安全性。
Current Gene Therapy
Title:Biodistribution of LV-TSTA Transduced Rat Bone Marrow Cells Used for “Ex-vivo” Regional Gene Therapy for Bone Repair
Volume: 15 Issue: 5
Author(s): Farhang Alaee, Cynthia Bartholomae, Osamu Sugiyama, Mandeep S. Virk, Hicham Drissi, Qian Wu, Manfred Schmidt and Jay R. Lieberman
Affiliation:
关键词: 病毒载体分布,骨修复,体外基因治疗及安全性。
摘要: “Ex vivo” regional gene therapy using lentiviral (LV) vectors to over-express bone morphogenetic protein 2 (BMP-2) is an effective way to enhance bone healing in animal models. Here, we evaluated two different “ex vivo” approaches using either “same day” rat bone marrow cells (SDRBMCs) or cultured rat bone marrow cells (C-RBMCs), both transduced with a LV based two-step transcriptional activation system overexpressing GFP (LV-TSTA-EGFP), to assess the fate of the transduced cells and the safety of this approach. The transduced cells were implanted in femoral defects of syngeneic rats. Animals were sacrificed at 4, 14, 28 and 56 days after surgery (n=5 per group). Viral copies were detectable in the defect site of SD-RBMC group and gradually declined at 8w (5 log decrease compared to 4d). In the C-RBMC animals, there was a 2-4 log decline in the viral copy numbers at 2w and 4w, but at 8w there was a relative rise (about 100 fold) in the number of the viral vectors in the defect site of 4 (out of 5) animals compared to the previous time points. For both gene transfer approaches, the pattern of tissue distribution was non-specific and no histological abnormalities were noted in either group. In summary, we demonstrated that the LV-TSTA transduced cells remain in the defect site for at least 56 days, though the numbers decreased over time. There were no consistent findings of viral copies in internal organs which is encouraging with respect to the development of this strategy for use in humans.
Export Options
About this article
Cite this article as:
Alaee Farhang, Bartholomae Cynthia, Sugiyama Osamu, Virk S. Mandeep, Drissi Hicham, Wu Qian, Schmidt Manfred and Lieberman R. Jay, Biodistribution of LV-TSTA Transduced Rat Bone Marrow Cells Used for “Ex-vivo” Regional Gene Therapy for Bone Repair, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812120229
DOI https://dx.doi.org/10.2174/1566523215666150812120229 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Research on the Preparation and Biological Activity of Maslinic Acid
Mini-Reviews in Medicinal Chemistry Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiating Between Primary Tumor, Metastatic Node and Normal Tissue in Head and Neck Cancer
Current Medical Imaging Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Investigation of Human Papilloma Virus Associated with Oral Cancer with an Insight into Diagnostic Approaches and Recent Patents
Recent Patents on Biomarkers Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology Novel 1,2,3-Triazole-functionalized pyrido[3',2':4,5]furo[3,2-d]pyrimidin- 4(3H)-one Derivatives: Synthesis, Anticancer Activity, CoMFA and CoMSIA Studies
Letters in Organic Chemistry Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Computational Docking Studies of Novel Heterocyclic Carboxamides as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery Modulators of Protein-Protein Interactions – Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules
Current Topics in Medicinal Chemistry An Efficient Approach for Diagnosis System of Cervical Cancer Using Image Fusion to Prevent Earlier Death in Women
Current Medical Imaging A Comprehensive Review on Cross-talk of Human Papilloma Virus Oncoproteins and Developmental/Self-Renewal Pathways During the Pathogenesis of Uterine Cervical Cancer
Current Molecular Medicine Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics Skeletal Muscle Cell Behavior After Physical Agent Treatments
Current Pharmaceutical Design Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Gold Nanoparticles as Carrier(s) for Drug Targeting and Imaging
Pharmaceutical Nanotechnology